JP6450767B2 - 血漿アフェレーシスデバイス - Google Patents

血漿アフェレーシスデバイス Download PDF

Info

Publication number
JP6450767B2
JP6450767B2 JP2016543045A JP2016543045A JP6450767B2 JP 6450767 B2 JP6450767 B2 JP 6450767B2 JP 2016543045 A JP2016543045 A JP 2016543045A JP 2016543045 A JP2016543045 A JP 2016543045A JP 6450767 B2 JP6450767 B2 JP 6450767B2
Authority
JP
Japan
Prior art keywords
plasma
gal
blood
patient
separator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016543045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507683A (ja
Inventor
エリアス，アイザック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eliaz Therapeutics inc
Original Assignee
Eliaz Therapeutics inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/141,509 external-priority patent/US9549953B2/en
Application filed by Eliaz Therapeutics inc filed Critical Eliaz Therapeutics inc
Publication of JP2017507683A publication Critical patent/JP2017507683A/ja
Application granted granted Critical
Publication of JP6450767B2 publication Critical patent/JP6450767B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3403—Regulation parameters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3672—Means preventing coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A61M1/3696—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0445—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/09—Body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/005—Parameter used as control input for the apparatus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
    • A61M2230/06—Heartbeat rate only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/205—Blood composition characteristics partial oxygen pressure (P-O2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/30—Blood pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
JP2016543045A 2013-12-27 2014-05-20 血漿アフェレーシスデバイス Active JP6450767B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/141,509 2013-12-27
US14/141,509 US9549953B2 (en) 2011-12-08 2013-12-27 Galectin-3 plasmapheresis therapy
PCT/US2014/038694 WO2015099826A1 (en) 2013-12-27 2014-05-20 Plasmapheresis device

Publications (2)

Publication Number Publication Date
JP2017507683A JP2017507683A (ja) 2017-03-23
JP6450767B2 true JP6450767B2 (ja) 2019-01-09

Family

ID=53479471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016543045A Active JP6450767B2 (ja) 2013-12-27 2014-05-20 血漿アフェレーシスデバイス

Country Status (18)

Country Link
US (2) US10953148B2 (enExample)
EP (1) EP3086870B1 (enExample)
JP (1) JP6450767B2 (enExample)
KR (1) KR20160102440A (enExample)
CN (2) CN105828900A (enExample)
AU (1) AU2014370393B2 (enExample)
BR (1) BR112016013876B1 (enExample)
CA (1) CA2932902C (enExample)
DK (1) DK3086870T3 (enExample)
ES (1) ES2713388T3 (enExample)
IL (1) IL246086B (enExample)
MX (1) MX369551B (enExample)
MY (1) MY184230A (enExample)
NZ (1) NZ720820A (enExample)
RU (1) RU2680677C2 (enExample)
SG (2) SG11201604881TA (enExample)
WO (1) WO2015099826A1 (enExample)
ZA (1) ZA201604453B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10828413B2 (en) * 2015-03-27 2020-11-10 Eliaz Therapeutics, Inc. Patient selective apheresis
EP3319513B1 (en) * 2015-07-07 2022-12-07 Khalil, Nashwa Autoimmune mechanical immunomodulation
US12121642B2 (en) 2015-07-07 2024-10-22 AMINA Sciences LLC Autoimmune mechanical immunomodulation
US11383015B2 (en) * 2016-01-11 2022-07-12 Fenwal, Inc. System and method for plasma purification prior to mononuclear cell collection
ES2900302T3 (es) * 2016-04-28 2022-03-16 Alkahest Inc Fracciones de plasma como terapia para el crecimiento y la progresión del tumor
KR101844513B1 (ko) 2016-08-11 2018-04-02 삼성전자주식회사 단층 영상 처리 장치 및 단층 영상 처리 방법
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
WO2019172836A1 (en) * 2018-03-08 2019-09-12 Glycorex Transplantation Ab A protein-binding product, a device contaning said protein-binding product and a method for extracorporeal reduction of the level of protein in blood plasma
WO2019195414A1 (en) 2018-04-03 2019-10-10 Fenwal, Inc. Plasmapheresis methods
EP3607978A1 (de) * 2018-08-06 2020-02-12 Pentracor GmbH Vereinfachte regeneration von apheresesäulen
US20200360426A1 (en) * 2019-05-16 2020-11-19 Isaac Eliaz Protocol and composition for suppression of allergic responses
KR20210043207A (ko) * 2019-10-11 2021-04-21 주식회사 싸이토딕스 비편향적 순환종양세포 연속 분리 장치 및 방법
JP2023510866A (ja) * 2020-01-13 2023-03-15 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体および使用方法
KR102718437B1 (ko) * 2020-07-20 2024-10-16 울산과학기술원 유체 장치를 이용하여 혈액 내 감염성 물질 또는 혈전을 제거하는 혈액 투석 장치 및 혈액 투석 방법
CN113559344A (zh) * 2021-08-16 2021-10-29 赛若麦得（上海）生物技术有限公司 低容量血浆置换设备
ES2940917B2 (es) * 2023-02-22 2023-11-30 Tecnic Biotech S L Un filtro de aféresis y un método para la eliminación de platino residual en sangre

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625212A (en) 1969-07-09 1971-12-07 North American Biolog Inc Eliminating mistakes in plasmapheresis
FR2351665A1 (fr) * 1976-05-21 1977-12-16 Elf Aquitaine Procede de purification de preparations possedant notamment une activite interferon, preparations purifiees ainsi obtenues et leur application en tant que medicament
US4384954A (en) * 1980-04-16 1983-05-24 Kuraray Co., Ltd. Column for adsorption of blood proteins
US4605394A (en) * 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
US4464167A (en) * 1981-09-03 1984-08-07 Haemonetics Corporation Pheresis apparatus
US4531932A (en) * 1981-11-27 1985-07-30 Dideco S.P.A. Centrifugal plasmapheresis device
GB2192633A (en) * 1986-06-13 1988-01-20 Royal Postgrad Med School Endotoxin removal
US5782792A (en) * 1986-11-21 1998-07-21 Cypress Bioscience, Inc. Method for treatment of rheumatoid arthritis
DE3926539A1 (de) * 1989-08-11 1991-02-14 Braun Melsungen Ag Verwendung von tentakel-kationenaustauschern zur selektiven eliminierung von low-density-lipoproteinen (ldl), fibrinogen und/oder harnstoff aus fluessigkeiten
US5348533A (en) * 1992-08-27 1994-09-20 Haemoentics Corporation Pheresis apparatus
IT1271593B (it) * 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
US6245038B1 (en) * 1997-01-07 2001-06-12 Helmut Borberg Method for treatment of ophthalmological diseases
US6061590A (en) * 1997-06-03 2000-05-09 Transonic Systems, Inc. Method and apparatus for predicting intradialytic morbid events through the monitoring of a central blood volume
US6627151B1 (en) 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
US20020198487A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in physiologic fluids
US6274566B1 (en) 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
US6462029B1 (en) 1999-02-23 2002-10-08 Econugenics Compositions and methods for treating mammals with modified alginates and modified pectins
WO2000066197A1 (en) * 1999-04-30 2000-11-09 Children's Hospital Medical Center Hemofiltration system
US20060060520A1 (en) * 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
WO2003101511A1 (fr) * 2002-05-30 2003-12-11 Toray Industries, Inc. Adsorbant d'une substance immunosuppressive, colonne de circulation extracorporelle, et procede de traitement du cancer
JP2005535394A (ja) 2002-08-13 2005-11-24 アルビオス テクノロジーズ インコーポレーティッド 選択的血漿交換方法
US7531133B2 (en) * 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
CA2563904A1 (en) * 2004-02-18 2005-08-25 Plasma Ventures Pty Ltd Isolated plasma and method for hyperimmunisation and plasma collection
US8105491B2 (en) * 2004-04-27 2012-01-31 Vital Therapies, Inc. Metabolic detoxification and method
AU2005240082B2 (en) * 2004-04-30 2009-07-23 Innatus Corporation Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients
US8426567B2 (en) 2005-08-26 2013-04-23 Econugenics, Inc. Method for enhancing mammalian immunological function
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
DE102005061715A1 (de) * 2005-12-22 2007-06-28 Biobarries Gmbh Prozess zur Entfernung von C-reactivem Protein aus biologischen Flüssigkeiten durch Apherese
EP1875957B1 (en) * 2006-07-07 2010-03-03 Gambro Lundia AB Plasma separation membrane
JP2010131033A (ja) * 2007-03-16 2010-06-17 Medical Science Co Ltd 医療用吸着剤
US20100210989A1 (en) * 2008-12-23 2010-08-19 Janet Lesley Macpherson Processing blood
US8454547B2 (en) * 2009-02-25 2013-06-04 The Invention Science Fund I, Llc Device, system, and method for controllably reducing inflammatory mediators in a subject
DE102009037015A1 (de) * 2009-08-07 2011-02-17 Michael Hajek Vorrichtung und Verfahren zur Eliminierung von bioschädlichen Stoffen aus Körperflüssigkeiten
WO2011044369A1 (en) * 2009-10-08 2011-04-14 Otsuka Pharmaceutical Co., Ltd. An immunoactivation blood perfusion filter for the treatment of malignant tumors
WO2011112873A2 (en) * 2010-03-10 2011-09-15 Paul Tebbey Extracorporeal immunoadsorption treatment
EP2569253A4 (en) * 2010-05-14 2013-10-02 Beth Israel Hospital EXTRACORPORAL DEVICES AND METHOD FOR TREATING COMPLICATIONS DURING PREGNANCY
WO2012163544A1 (en) * 2011-06-01 2012-12-06 Biopheresis Technologies, Inc. Removal of soluble tumor necrosis factor receptor 2 (stnfr2)
RU2545859C1 (ru) 2011-12-08 2015-04-10 Исаак ЭЛИАС Уменьшение уровней галектина-3 посредством плазмафереза
US9549953B2 (en) 2011-12-08 2017-01-24 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
JP6404211B2 (ja) * 2012-05-14 2018-10-10 ザ チルドレンズ メディカル センター コーポレーション 体外血液改質のためのシステムおよび方法
WO2013179143A2 (en) * 2012-06-01 2013-12-05 Biopheresis Technologies, Inc. Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors

Also Published As

Publication number Publication date
CN105828900A (zh) 2016-08-03
US20160317734A1 (en) 2016-11-03
WO2015099826A1 (en) 2015-07-02
EP3086870A1 (en) 2016-11-02
KR20160102440A (ko) 2016-08-30
MX369551B (es) 2019-11-12
MY184230A (en) 2021-03-29
SG10201804910UA (en) 2018-07-30
RU2016130573A (ru) 2018-02-01
EP3086870A4 (en) 2017-02-15
AU2014370393A1 (en) 2016-06-23
US20210138143A1 (en) 2021-05-13
RU2016130573A3 (enExample) 2018-03-23
CA2932902A1 (en) 2015-07-02
EP3086870B1 (en) 2019-01-02
IL246086B (en) 2021-04-29
US10953148B2 (en) 2021-03-23
NZ720820A (en) 2019-10-25
AU2014370393B2 (en) 2018-09-20
SG11201604881TA (en) 2016-08-30
CN112691252A (zh) 2021-04-23
CA2932902C (en) 2020-04-21
JP2017507683A (ja) 2017-03-23
BR112016013876A2 (enExample) 2017-09-19
ES2713388T3 (es) 2019-05-21
ZA201604453B (en) 2017-09-27
DK3086870T3 (en) 2019-03-18
MX2016008420A (es) 2016-10-12
RU2680677C2 (ru) 2019-02-25
IL246086A0 (en) 2016-07-31
BR112016013876B1 (pt) 2022-03-22

Similar Documents

Publication Publication Date Title
JP6450767B2 (ja) 血漿アフェレーシスデバイス
Dellepiane et al. Detrimental cross-talk between sepsis and acute kidney injury: new pathogenic mechanisms, early biomarkers and targeted therapies
Altobelli et al. Therapeutic plasmapheresis: a revision of literature
US10213462B2 (en) Galectin-3 plasmapheresis therapy
DE112005001901T5 (de) Einfangen und entfernen von Biomolekülen aus Körperflüssigkeiten unter Verwendung von partiellen molekularen Abdrücken
Luo et al. Platelets protect lung from injury induced by systemic inflammatory response
US20180169319A1 (en) Treatment of cancer by manipulating the immune system
US20070092509A1 (en) Method for ex-vivo separation of apoptotic chromatin fragments from blood or plasma for prevention and treatment of diverse human diseases
WO2015153287A1 (en) Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome
US9265875B2 (en) Methods for treating blood composition and function disorders wherein a patient's blood plasma is extracorporeally contacted with donor blood or modified donor blood
Crump et al. Use of therapeutic plasmapheresis in a case of canine immune‐mediated hemolytic anemia
Hickstein et al. AB0 incompatible kidney transplantation using unspecific immunoadsorption
HK1228831B (en) Plasmapheresis device
HK1228831A1 (en) Plasmapheresis device
JP2024536529A (ja) 全血のアフェレーシス
AU2016262697B2 (en) Galectin-3 plasmapheresis therapy
Yoshihara et al. Impact of the use of hydroxyethyl starch in granulocyte apheresis using Spectra Optia
VanZalen et al. Leukocyte filtration and leukocyte modulation therapy during extracorporeal cardiopulmonary resuscitation in a porcine model of prolonged cardiac arrest
Pták Changes of selected hematologic parameters during long-term immunoadsorption therapy
Mehta et al. WJCCM
CN116568345A (zh) 增加红细胞计数的技术
Miyamoto et al. Preliminary studies for the development of a second generation granulocytapheresis (G-CAP) column. Part II: in vitro and ex vivo studies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180320

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181210

R150 Certificate of patent or registration of utility model

Ref document number: 6450767

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250